These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27089606)

  • 1. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective].
    Lalive PH
    Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606
    [No Abstract]   [Full Text] [Related]  

  • 2. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

  • 3. Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis.
    Giovannoni G
    Mult Scler; 2011 Mar; 17(3):259-61. PubMed ID: 21362756
    [No Abstract]   [Full Text] [Related]  

  • 4. Can ad hoc analyses of clinical trials help personalize treatment decisions?
    Biltaji E; Kumar SS; Enioutina EY; Sherwin CMT
    Br J Clin Pharmacol; 2017 Nov; 83(11):2337-2338. PubMed ID: 28815756
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapies: Progressive steps.
    Dolgin E
    Nature; 2016 Nov; 540(7631):S7-S9. PubMed ID: 27902682
    [No Abstract]   [Full Text] [Related]  

  • 6. Progress in Multiple Sclerosis Research: An Example of Bedside to Bench.
    Hauser SL
    JAMA; 2020 Sep; 324(9):841-842. PubMed ID: 32379266
    [No Abstract]   [Full Text] [Related]  

  • 7. New Drug For Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
    [No Abstract]   [Full Text] [Related]  

  • 8. Towards treating progressive multiple sclerosis.
    Thompson A; Ciccarelli O
    Nat Rev Neurol; 2020 Nov; 16(11):589-590. PubMed ID: 33024328
    [No Abstract]   [Full Text] [Related]  

  • 9. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Ramanathan M; Kolb C; Hojnacki D; Minagar A; Zivadinov R
    Expert Opin Biol Ther; 2017 Sep; 17(9):1163-1172. PubMed ID: 28658986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
    Taupin P
    Expert Opin Ther Pat; 2011 Jan; 21(1):111-4. PubMed ID: 21155688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.
    Wallin MT
    Mult Scler; 2018 Aug; 24(9):1159-1161. PubMed ID: 29468931
    [No Abstract]   [Full Text] [Related]  

  • 13. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Yes.
    Piehl F; Hillert J
    Mult Scler; 2018 Aug; 24(9):1157-1159. PubMed ID: 29468952
    [No Abstract]   [Full Text] [Related]  

  • 14. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary.
    Cree BA
    Mult Scler; 2018 Aug; 24(9):1161-1162. PubMed ID: 29468947
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond ocrelizumab in primary progressive multiple sclerosis.
    Williams T; Chataway J
    Nat Rev Neurol; 2022 Nov; 18(11):641-642. PubMed ID: 36138171
    [No Abstract]   [Full Text] [Related]  

  • 16. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial.
    Romme Christensen J; Ratzer R; Börnsen L; Lyksborg M; Garde E; Dyrby TB; Siebner HR; Sorensen PS; Sellebjerg F
    Neurology; 2014 Apr; 82(17):1499-507. PubMed ID: 24682973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.
    Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM
    Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness and predictive values in PPMS: an uncertain message.
    Cutter GR; Lublin FD
    Neurology; 2008 Mar; 70(13 Pt 2):1061-2. PubMed ID: 18362265
    [No Abstract]   [Full Text] [Related]  

  • 19. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for secondary progressive multiple sclerosis: a case series.
    Rommer PS; Patejdl R; Winkelmann A; Benecke R; Zettl UK
    CNS Drugs; 2011 Jul; 25(7):607-13. PubMed ID: 21699272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.